Becton, Dickinson and Company $BDX Stock Position Decreased by Fiduciary Management Inc. WI

Fiduciary Management Inc. WI reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 7.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 1,103,441 shares of the medical instruments supplier’s stock after selling 86,747 shares during the period. Becton, Dickinson and Company comprises 2.4% of Fiduciary Management Inc. WI’s holdings, making the stock its 7th biggest position. Fiduciary Management Inc. WI’s holdings in Becton, Dickinson and Company were worth $214,145,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in BDX. Wellington Management Group LLP lifted its position in shares of Becton, Dickinson and Company by 9,056.3% during the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock valued at $979,290,000 after buying an additional 5,174,944 shares in the last quarter. Vanguard Group Inc. raised its stake in Becton, Dickinson and Company by 13.0% during the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after purchasing an additional 4,223,149 shares during the period. Northwestern Mutual Wealth Management Co. raised its stake in Becton, Dickinson and Company by 23,219.2% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock valued at $769,397,000 after purchasing an additional 4,137,888 shares during the period. Norges Bank bought a new stake in Becton, Dickinson and Company during the 4th quarter valued at approximately $734,321,000. Finally, First Eagle Investment Management LLC raised its stake in Becton, Dickinson and Company by 16.5% during the 4th quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock valued at $2,260,139,000 after purchasing an additional 1,651,592 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BDX. Argus decreased their target price on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research note on Monday, March 23rd. Piper Sandler decreased their target price on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Citigroup decreased their target price on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th. JPMorgan Chase & Co. decreased their target price on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 10th. Finally, Weiss Ratings downgraded Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company has an average rating of “Hold” and an average target price of $183.64.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $151.33 on Friday. The company has a market cap of $41.70 billion, a P/E ratio of 38.31, a P/E/G ratio of 10.70 and a beta of 0.22. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. The business’s 50 day moving average price is $150.72 and its 200-day moving average price is $175.54. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.13. The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Sell-side analysts predict that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.8%. Becton, Dickinson and Company’s payout ratio is currently 106.33%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 2,913 shares of company stock worth $426,806. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.